Next Article in Journal
Preparation and In Vitro/In Vivo Characterization of Porous Sublingual Tablets Containing Ternary Kneaded Solid System of Vinpocetine with β-Cyclodextrin and Hydroxy Acid
Previous Article in Journal
Liquisolid Systems to Improve the Dissolution of Furosemide
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation

by
Mahendra NAKARANI
1,*,
Priyal PATEL
2,
Jayvadan PATEL
3,
Pankaj PATEL
4,
Rayasa S. R. MURTHY
4 and
Subhash S. VAGHANI
5
1
Unison Pharmaceuticals, Ahmedabad, Gujarat, India
2
S. K. Patel college of Pharm Edu & Res, Ganpat University, Gujarat, India
3
Nootan pharmacy college, Visnagar, Gujarat, India
4
TIFAC-CORE in NDDS, The M.S.University of Baroda, India
5
Smt. R. B. Patel Mahila Pharmacy College, Atkot, India
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2010, 78(2), 345-362; https://doi.org/10.3797/scipharm.0908-12
Submission received: 28 April 2009 / Accepted: 14 April 2010 / Published: 26 April 2010

Abstract

Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and distilled water as an aqueous medium using the Pearl Milling technique. The optimized formulation was characterized in terms of particle size distribution, surface morphology, drug-surfactant interaction, drug content, saturation solubility, osmolarity, and stability. The nanoparticles consisting of Poloxamer-bound cyclosporin A with a mean diameter of 213 nm revealed a spherical shape and 5.69 fold increased saturation solubility as compared to the parent drug. The formulation was found to be iso-osmolar with blood and stable up to 3 months at 2–8°C. In-vivo studies were carried out in albino rats and the pharmacokinetic parameters were compared with a marketed formulation, which indicated better results of the prepared formulation than the marketed one.
Keywords: Cyclosporine A; Nanosuspension; Scanning electron microscopy; Poloxamer; Osmolarity Cyclosporine A; Nanosuspension; Scanning electron microscopy; Poloxamer; Osmolarity

Share and Cite

MDPI and ACS Style

NAKARANI, M.; PATEL, P.; PATEL, J.; PATEL, P.; MURTHY, R.S.R.; VAGHANI, S.S. Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation. Sci. Pharm. 2010, 78, 345-362. https://doi.org/10.3797/scipharm.0908-12

AMA Style

NAKARANI M, PATEL P, PATEL J, PATEL P, MURTHY RSR, VAGHANI SS. Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation. Scientia Pharmaceutica. 2010; 78(2):345-362. https://doi.org/10.3797/scipharm.0908-12

Chicago/Turabian Style

NAKARANI, Mahendra, Priyal PATEL, Jayvadan PATEL, Pankaj PATEL, Rayasa S. R. MURTHY, and Subhash S. VAGHANI. 2010. "Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation" Scientia Pharmaceutica 78, no. 2: 345-362. https://doi.org/10.3797/scipharm.0908-12

Article Metrics

Back to TopTop